TG Therapeutics Inc. (NASDAQ: TGTX) reported fourth‑quarter and full‑year 2025 financial results, posting $192.6 million in total revenue for Q4 and $616.3 million for the year. BRIUMVI, the company’s flagship anti‑CD20 therapy for relapsing multiple sclerosis, generated $182.7 million in U.S. net product revenue in Q4 and $594.1 million for the year, representing a 92% year‑over‑year increase and underscoring the drug’s expanding market share and global availability.
The company’s earnings per share for Q4 2025 were $0.14, a miss of $0.23 against analyst expectations of $0.37. The miss reflects higher operating expenses and the absence of a one‑time tax benefit that was present in the prior year. In contrast, full‑year 2025 net income rose to $447.2 million from $23.4 million in 2024, largely driven by a non‑recurring income tax benefit of approximately $339.8 million. Gross profit margin for 2025 was 85%, indicating strong pricing power and efficient cost management.
Management highlighted the continued momentum of BRIUMVI, noting that “2025 was a strong year of execution for TG Therapeutics, driven by continued momentum for BRIUMVI and meaningful progress across our organization. BRIUMVI delivered significant year‑over‑year growth in the U.S., supported by increasing adoption and expanding global availability, while we advanced multiple late‑stage clinical programs and strengthened our financial position.” The company also emphasized its disciplined capital allocation, stating “As we enter 2026, we are focused on building on this foundation. With strong financial guidance, several important clinical milestones ahead, and a disciplined approach to operations, we believe we are well positioned to continue delivering value for patients, healthcare providers, and shareholders.”
TG Therapeutics raised its 2026 revenue guidance to $875 million–$900 million, reflecting confidence in BRIUMVI’s continued sales growth and progress in its late‑stage pipeline. The company’s share repurchase program, which completed $100 million in Q3 2025 and authorized an additional $100 million, signals a commitment to returning value to shareholders while maintaining a robust cash position of $199.5 million at year‑end.
The market reacted negatively to the earnings release, citing the significant EPS miss as the primary driver of the downturn. Despite strong revenue growth and a raised guidance, the earnings miss underscored the company’s ongoing challenge of translating top‑line expansion into profitability, a concern that investors weighed heavily in their assessment of the company’s near‑term performance.
Bioscience analysts note that TG Therapeutics’ BRIUMVI remains the most affordable anti‑CD20 therapy in the U.S., competing against Roche’s Ocrevus and Novartis’s Kesimpta. The company is also pursuing new dosing regimens, including a consolidated IV schedule and a subcutaneous formulation, and exploring indications beyond multiple sclerosis. Its pipeline includes azer‑cel, an allogeneic CAR‑T therapy for autoimmune diseases, positioning TG Therapeutics for diversified growth beyond its flagship product.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.